Goldman Sachs Maintains Neutral on Cerevel Therapeutics Hldg, Lowers Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Madhu Kumar maintains a Neutral rating on Cerevel Therapeutics Hldg (NASDAQ:CERE) and lowers the price target from $31 to $30.
May 23, 2023 | 11:28 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs maintains a Neutral rating on Cerevel Therapeutics Hldg and lowers the price target from $31 to $30.
The news directly mentions Cerevel Therapeutics Hldg (CERE) and the lowered price target by Goldman Sachs. The Neutral rating remains unchanged, indicating that the stock is not expected to outperform or underperform the market in the short term. The lowered price target may have a neutral impact on the stock price, as it is only a $1 decrease.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100